Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dendritic cell vaccine - CreaGene

Next Previous
Drug Profile

Dendritic cell vaccine - CreaGene

Alternative Names: CreaVax-BC; CreaVax-HCC; CreaVax-HCC Inj.; CreaVax-PC; CreaVax-PC Inj.; CreaVax-RA Inj.; CreaVax-RCC; CreaVax-RCC Inj.; Dendritic cell vaccine for glioblastoma multiforme - CreaGene; Renal cell carcinoma vaccine - CreaGene/Dong-A

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Creagene
  • Developer Dong-A ST; JW CreaGene
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase III Liver cancer
  • Phase II Rheumatoid arthritis
  • Phase I/II Glioblastoma; Prostate cancer

Most Recent Events

  • 28 May 2021 Beroni Group in collaboration with Tella plans a clinical trial in Cancer in Japan and China
  • 28 May 2021 Beroni Group signs a Memorandum of Understanding with Tella for collaboration in Cancer in Japan and China
  • 24 Sep 2019 KCT0003302- updated KDM and added development lines, edited intro, changed MoA to immunostimulants
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top